Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cause-specific mortality in patients with psoriasis and psoriatic arthritis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucose metabolism in patients with psoriasis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cohort profile: the clinical 'Psoriasis in Adolescents' (PIA) cohort in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: There are limited data regarding causes of mortality in patients with psoriasis or psoriatic arthritis (PsA).

OBJECTIVES: This retrospective cohort study evaluated the risk and leading causes of mortality in patients with psoriasis or PsA.

METHODS: Individuals with a hospital-based diagnosis of PsA or psoriasis were identified using the Danish National Patient Registry. Matched control individuals were identified from the general population. The main outcome measures were risk of death and cause-specific mortality in patients with psoriasis or PsA.

RESULTS: Death rates per 1000 patient-years (with 95% confidence intervals) vs. controls were 22·3 (19·7-24·9) vs. 13·9 (11·8-16·0) for patients with psoriasis and 10·8 (8·9-12·8) vs. 11·6 (9·6-13·6) for patients with PsA. Survival, according to stratified hazard ratios (HRs), was significantly lower in patients with psoriasis than in controls (HR 1·74, P < 0·001), but not in patients with PsA (HR 1·06, P = 0·19). Significantly increased risk of death was observed in patients with psoriasis vs. controls due to a number of causes; the highest risks were observed for diseases of the digestive system; endocrine, nutritional and metabolic diseases; and certain infectious and parasitic diseases (HRs 3·61, 3·02 and 2·71, respectively). In patients with PsA, increased mortality was observed only for certain infectious and parasitic diseases (HR 2·80) and diseases of the respiratory system (HR 1·46). Patients with psoriasis died at a younger age than controls (mean age 71·0 vs. 74·5 years, P < 0·001).

CONCLUSIONS: Patients with severe psoriasis have increased mortality risk compared with matched controls, due to a number of causes. Evidence to support an increased risk for patients with PsA was less convincing.

OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind180
Udgave nummer1
Sider (fra-til)100-107
Antal sider8
ISSN0007-0963
DOI
StatusUdgivet - jan. 2019

Bibliografisk note

© 2018 British Association of Dermatologists.

ID: 58099364